Overview of Roche key data at AAN covering new analysis from Ocrevus, satralizumab SakuraSky phase III data, risdiplam one year part I FIREFISH and SUNFISH data and dose selection data for the phase III study in Huntington's Disease
Roche Neuroscience and Rare Disease franchise update
Q&A
Karl Mahler, Head of Investor Relations
Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development
Karsten Jung, Therapeutic Area Head Neuroscience and Rare Diseases